Taken together, these pilot studies in the rhesus macaque model of HIV infection suggest that autologous CAR/CXCR5-T cell therapy may be a viable tool for the treatment of HIV infection in ART-suppressed individuals after ART cessation. This evidence concerns the gene CXCR5 and HIV infectious disease.